No products in the cart.
Pre-made Inotuzumab benchmark antibody ( Whole mAb ADC, anti-CD22 therapeutic antibody, Anti-SIGLEC2/SIGLEC-2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-275
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Inotuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
| Products Name (INN Index) | Pre-Made Inotuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody |
|---|---|
| INN Name | Inotuzumab |
| Target | CD22 |
| Format | Whole mAb ADC |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2004 |
| Year Recommended | 2005 |
| Companies | Alliance for Clinical Trials in Oncology,Cancer Research UK,Case Comprehensive Cancer Center,Children's Oncology Group,Erasmus MC,M. D. Anderson Cancer Center,National Cancer Institute (USA),Pfizer,S |
| Conditions Approved | Precursor cell lymphoblastic leukaemia-lymphoma |
| Conditions Active | Precursor B-cell lymphoblastic leukaemia-lymphoma,Chronic myeloid leukaemia |
| Conditions Discontinued | Acute biphenotypic leukaemia,Burkitt's lymphoma,Diffuse large B cell lymphoma,Non-Hodgkin's lymphoma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD22 |
| Package |
Previous slide
Next slide
